Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!

Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!

💊 Can weight loss achieved with injectable GLP-1 therapies be maintained using an oral agent?   The ATTAIN-MAINTAIN phase 3b trial published in Nature Medicine evaluated once-daily oral orforglipron after prior tirzepatide or semaglutide therapy. Patients maintained substantially more prior weight reduction versus placebo over 52 weeks, while preserving cardiometabolic benefits. 🌍⚖️   A fascinating glimpse into the future of scalable obesity care: oral incretin therapy may improve adherence, accessibility, and long-term maintenance.   #Obesity #GLP1 #Orforglipron...

Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!

👁️ New NEJM correspondence highlights a potentially important ophthalmic signal linked to dulaglutide therapy. Two patients developed choroidal lymphoid hyperplasia with painless visual loss within months of GLP-1 receptor agonist initiation. Remarkably, ocular and systemic findings rapidly resolved after stopping dulaglutide. As GLP-1 therapies expand across diabetes, obesity, and cardiometabolic medicine, clinicians should remain vigilant for emerging ocular adverse events. A fascinating intersection of endocrinology, immunology, and ophthalmology. 🔬💉👓 #NEJM #GLP1 #Dulaglutide...

Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!

🫀 Scar. Signal. Survival.   A major new JAMA study from the NHLBI Hypertrophic Cardiomyopathy Registry followed 2,698 patients for nearly 7 years and demonstrated that advanced cardiac magnetic resonance imaging and NT-proBNP markedly improve prediction of adverse outcomes in hypertrophic cardiomyopathy.   📌 Key findings: • Late gadolinium enhancement (fibrosis burden) strongly predicted events • LGE ≥9% of LV mass substantially increased risk • LV mass index, LV systolic dysfunction, and NT-proBNP independently predicted outcomes • Traditional markers alone may miss...

Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!

🧠 Six landmark stroke investigations published in NEJM, JAMA, and Lancet are redefining modern reperfusion science.   🔹 ORIENTAL-MeVO: Thrombectomy improved outcomes in selected medium-vessel occlusion strokes. 🔹 TNK-PLUS: Bridging tenecteplase before EVT in the late window showed no added benefit. 🔹 CHOICE-2: Intra-arterial alteplase after successful thrombectomy improved excellent recovery but raised mortality concerns. 🔹 INSTANT: Early tirofiban after inadequate tenecteplase response improved 90-day outcomes. 🔹 TAPIS: Early ticagrelor + aspirin after thrombolysis...

Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!

😴🧠 How much sleep is “just right” for healthy ageing? A remarkable Nature study of ~500,000 UK Biobank participants demonstrated a striking U-shaped relationship between sleep duration and biological ageing across 23 ageing clocks, 17 organs, and 3 omics platforms. 🌙🧬 Both short (<6 h) and long (>8 h) sleep were associated with accelerated ageing, higher systemic disease burden, and increased all-cause mortality. The biologic “sweet spot” appeared to be ~6–8 hours/night. ⏳❤️ An elegant reminder that sleep is not passive rest — it is active systemic repair....

Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!

🫀 Old drug. New evidence. Renewed relevance. Two major JAMA studies published in 2026 revisit the role of digoxin/digitalis glycosides in modern cardiovascular care. 📊 A meta-analysis of 9,013 patients with HFmrEF/HFrEF showed reduced worsening heart failure events without increased mortality. 🌍 The Dig-RHD randomized trial from India demonstrated that digoxin reduced death or worsening heart failure in symptomatic rheumatic heart disease with minimal toxicity. Key message: 💊 Digoxin may still have an important role as affordable adjunctive therapy—especially in resource-limited...

Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!

🐍⚕️ Before modern hospitals, there were the healing temples of Asclepius — where medicine, ritual, dreams, and compassion converged.   Son of Apollo, trained by the wise centaur Chiron, Asclepius became the enduring symbol of healing in Greek civilization. His daughters — Hygieia, Panacea, and Iaso — represented health, cure, and recovery itself.   Even today, the Rod of Asclepius remains the universal emblem of medicine. 🌿   A reminder that the art of healing has always been more than science alone — it is wisdom, empathy, and hope.

Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!

🧬 Predict. Prevent. Protect: The APOL1 Proteomic Revolution A fascinating new study in Nature Medicine describes a 9-protein APOL1 Proteomic Risk Score (APRS) capable of predicting kidney disease progression years before chronic kidney disease becomes clinically apparent. Among individuals of African ancestry with APOL1 high-risk genotypes and preserved kidney function, APRS achieved a remarkable time-dependent AUC of ~86%, substantially outperforming traditional clinical scores and polygenic risk tools. This work moves us closer to precision nephrology: identifying who is truly at risk,...

Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!

🧠🎙️ New infographic from Dr RR Baliga’s Podkast for the Kurious Doc: “Colonoscopy, Cancer & Competing Risks.”   Two major 2026 studies from The Lancet and JAMA reshape how we think about colorectal cancer screening and surveillance.   🔹 The NordICC trial showed reduced colorectal cancer incidence with colonoscopy, but no significant mortality reduction after 13 years. 🔹 In adults ≥75 years with prior adenomas, non-colorectal cancer mortality far exceeded colorectal cancer risk, highlighting the importance of frailty and individualized decision-making.  ...

Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!

🧠 Three major stroke trials published in JAMA this week may reshape adjunctive reperfusion strategies in acute ischemic stroke.   🔹 TNK-PLUS: Tenecteplase before thrombectomy in late-window stroke showed no added functional benefit. 🔹 CHOICE-2: Intra-arterial alteplase after successful thrombectomy improved excellent neurological recovery, though mortality signals warrant caution. 🔹 INSTANT: Early tirofiban after inadequate tenecteplase response significantly improved 90-day outcomes in non-large vessel occlusion stroke.   Together, these studies highlight a growing shift...